How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Generative AI is infiltrating everything you do online, including how you find information. If you're bored with traditional search, check out the top AI search engines we've tried. I’ve been writing ...

Binary options trading offers a high-risk, high-reward way to speculate on short-term price movements. Unlike traditional options, binary options settle with a fixed payout either the trade ends “in ...

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. I've been testing PC and ...

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. Our team tests, rates, and ...